|
|
|
20.11.26 - 00:00
|
US panel warns of China′s biotech rise, fuelling push to curb ties as Chinese firms unfazed (SCMP)
|
|
|
Fresh warnings from a US congressional advisory body about the rapid rise of China's biopharmaceutical sector are fuelling Washington's push to curb cross-border ties, analysts said, though China's industry appears largely unfazed.
China was gaining a “competitive advantage” in biopharmaceuticals, and Western firms were increasingly paying large upfront fees to license Chinese drugs thanks to the country's “growing innovative capacity”, the US-China Economic and Security Review Commission (USCC)......
|
|
|
|
|
|
|
|
|
|
|
|
|
19.11.26 - 11:00
|
RA Capital opens Shanghai office to tap Chinese biotech even as US investment rules tighten (SCMP)
|
|
|
Prominent healthcare-focused US venture capital firm RA Capital has expanded its China footprint with a new Shanghai office, aiming to tap innovation in the Chinese biotech ecosystem as US firms navigate Washington's escalating scrutiny of cross-border deals.
Boston-headquartered RA Capital now has 12 China-based staff members, including four investment professionals who started working in the country in the past few months, partner Josh Resnick said in an interview on Wednesday.
The firm's new......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18.11.26 - 10:42
|
Drägerwerk peilt bis 2030 eine Milliarde Euro mehr an Umsatz an - Aktie legt zu (DPA-AFX)
|
|
|
Der Erlös soll 2030 rund 4,5 Milliarden Euro erreichen, wie der SDax-Konzern am Mittwoch in Lübeck mitteilte. Dies wären eine Milliarde Euro mehr als 2025. Zum Plus sollen beide Sparten - Medizintechnik und Sicherheitstechnik - mit jeweils rund 500 Millionen Euro beitragen. Auch das Ergebnis vor Zinsen und Steuern (Ebit) soll kräftig zulegen. Die entsprechende Marge soll sich bis 2030 auf 10 bis 12 Prozent verbessern, nach 6,7 Prozent im vergangenen Jahr. Das kam an der Börse gut an: Der Aktienkurs legte um fast 5 Prozent zu..
|
|
|
18.11.26 - 09:00
|
China still has ′catching up to do′ to become biotech powerhouse, JPMorgan says (SCMP)
|
|
|
A lag in foundational research and looming geopolitical risks will weigh on China's bid to build a world-class biotechnology innovation ecosystem, even as the sector's overseas momentum remains strong, according to JPMorgan.
“In China, there is still some catching up to do in basic research, particularly in biological and pharmaceutical research,” said Yang Huang, head of China healthcare research at JPMorgan, during an interview on Wednesday.
To meet the “ambitious goal” set in the country's......
|
|
|
18.11.26 - 07:00
|
Yicura BioMed eyes IPO as CEO says Hong Kong biotech scene needs more patient capital (SCMP)
|
|
|
Hong Kong needs more “patient capital” and more talent capable of commercialising research and development to sustain the city's biotechnology ecosystem, according to a senior executive at a local biotech start-up.
Yicura BioMed, based in the Hong Kong Science Park, is heading towards an initial public offering (IPO) in the city as soon as practicable, CEO Xian Jin said in an interview.
“Biotech start-up fundraising in Hong Kong is never an easy game to play,” Jin said, adding that developing a......
|
|
|
|
|
|